Zhongjin Irradiation's (SZSE:300962) Returns Have Hit A Wall
Zhongjin Irradiation's (SZSE:300962) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So, when we ran our eye over Zhongjin Irradiation's (SZSE:300962) trend of ROCE, we liked what we saw.
如果你在尋找多倍回報的投資,有幾個事情需要注意。首先,我們希望識別出一個不斷增長的資本回報率(ROCE),同時伴隨一個不斷增加的資本使用基礎。基本上,這意味着公司有盈利的項目可以繼續再投資,這是一種複合增長的特徵。 所以,當我們查看中金輻照(SZSE:300962)資本回報率的趨勢時,我們對所看到的印象不錯。
What Is Return On Capital Employed (ROCE)?
我們對 Enphase Energy 的資本僱用回報率的看法:正如我們上面看到的,Enphase Energy 的資本回報率沒有提高,但它正在重新投資於業務。投資者必須認爲未來會有更好的前景,因爲股票表現良好,使持股五年以上的股東獲得了 690% 的收益。最終,如果基本趨勢持續存在,我們不會對它成爲一隻多頭股持有期很久很有信心。
If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Zhongjin Irradiation is:
如果你以前沒有接觸過資本回報率(ROCE),它衡量的是公司從其業務中使用的資本中產生的「回報」(稅前利潤)。對於中金輻照(Zhongjin Irradiation)這個計算的公式是:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
資本利用率 = 利息和稅前利潤(EBIT) ÷ (總資產 - 流動負債)
0.11 = CN¥117m ÷ (CN¥1.1b - CN¥66m) (Based on the trailing twelve months to September 2024).
0.11 = CN¥11700萬 ÷ (CN¥11億 - CN¥66m)(基於截至2024年9月的過去12個月數據)。
So, Zhongjin Irradiation has an ROCE of 11%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 9.0% it's much better.
因此,中金輻照的資本回報率爲11%。從絕對值來看,這是一個令人滿意的回報,但與醫療行業的平均水平9.0%相比則要好得多。
Historical performance is a great place to start when researching a stock so above you can see the gauge for Zhongjin Irradiation's ROCE against it's prior returns. If you'd like to look at how Zhongjin Irradiation has performed in the past in other metrics, you can view this free graph of Zhongjin Irradiation's past earnings, revenue and cash flow.
歷史業績是研究股票時一個很好的開始,因此您可以看到中金輻照的ROCE與其歷史回報的比較。如果您想查看中金輻照在其他指標上的歷史表現,可以查看這張中金輻照過去的收益、營業收入和現金流的免費圖表。
What Does the ROCE Trend For Zhongjin Irradiation Tell Us?
中金輻照的ROCE趨勢告訴我們什麼?
The trend of ROCE doesn't stand out much, but returns on a whole are decent. Over the past five years, ROCE has remained relatively flat at around 11% and the business has deployed 58% more capital into its operations. Since 11% is a moderate ROCE though, it's good to see a business can continue to reinvest at these decent rates of return. Over long periods of time, returns like these might not be too exciting, but with consistency they can pay off in terms of share price returns.
ROCE的趨勢並不突出,但整體回報還不錯。在過去五年中,ROCE保持在大約11%相對平穩,業務已經將58%的更多資本投入到運營中。然而,由於11%是一個適中的ROCE,因此看到業務能夠繼續以這些不錯的回報率進行再投資是很好的。在很長一段時間內,這樣的回報可能不會太令人興奮,但憑藉一致性,它們可能在股票價格回報方面帶來回報。
In Conclusion...
最後,同等資本下回報率較低的趨勢通常不是我們關注創業板股票的最佳信號。由於這些發展進行良好,因此投資者不太可能表現友好。自五年前以來,該股下跌了32%。除非這些指標朝着更積極的軌跡轉變,否則我們將繼續尋找其他股票。
In the end, Zhongjin Irradiation has proven its ability to adequately reinvest capital at good rates of return. Yet over the last three years the stock has declined 11%, so the decline might provide an opening. That's why we think it'd be worthwhile to look further into this stock given the fundamentals are appealing.
最後,中金輻照已證明其能夠以良好的回報率充分再投資資本。然而,在過去三年中,該股票已經下跌了11%,因此這一下跌可能提供了一個機會。這就是爲什麼我們認爲進一步研究這隻股票是值得的,因爲基本面是有吸引力的。
On a final note, we've found 1 warning sign for Zhongjin Irradiation that we think you should be aware of.
最後,我們發現中金輻照有一個警告信號,您應該注意。
While Zhongjin Irradiation isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.
雖然中金輻照的回報並不是最高,但請查看這張免費清單,其中列出了回報率高且資產負債表穩健的公司。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。